CD40LG and infection: The proportion of participants on ofatumumab who experienced at least 1 infection within 1 month prior to and until 1 month after IgM below LLN was 31.1% (52 of 167; 2 serious), versus 51.5% (400 of 777) with IgM at or above LLN (18 serious) [29].